Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.
Gilead Sciences, Inc. (Nasdaq: GILD) is a biopharmaceutical company focused on medicines for HIV, viral hepatitis, COVID‑19, cancer and inflammation. The GILD news feed highlights how the company’s research, collaborations and policy decisions translate into clinical programs, regulatory milestones and access initiatives across these therapeutic areas.
Investors and healthcare observers following GILD news will see regular updates on Gilead’s HIV portfolio, including clinical trial readouts such as the Phase 3 ARTISTRY‑1 and ARTISTRY‑2 studies of an investigational single‑tablet regimen combining bictegravir and lenacapavir for virologically suppressed adults with HIV. News also covers developments related to lenacapavir as a long‑acting option for HIV prevention and treatment, as well as agreements affecting key products like Biktarvy, including patent settlements disclosed by the company.
Oncology and cell therapy news is another major theme. Through Kite, a Gilead company, GILD‑related releases feature data on Yescarta for relapsed or refractory large B‑cell lymphoma, next‑generation bicistronic CAR T‑cell candidates KITE‑753 and KITE‑363 for B‑cell lymphomas, and anitocabtagene autoleucel (anito‑cel) for relapsed or refractory multiple myeloma. Updates often include efficacy and safety results from pivotal and early‑stage trials, as well as details on collaborations such as the partnership with Arcellx on anito‑cel and the research collaboration with OncoNano Medicine on ON‑BOARD encapsulation technology.
Gilead news also reflects broader corporate and policy activity, including agreements with the U.S. government related to drug pricing and access, philanthropic grants from the Gilead Foundation for metastatic breast cancer support, leadership appointments, investor conference presentations and quarterly financial announcements. Bookmark this page to monitor how these scientific, commercial, governance and access‑related developments shape the ongoing story of GILD.
Gilead Foundation (Nasdaq: GILD) announced a $12 million grant program funding 33 community organizations across 14 states and the District of Columbia through a two-year Community Health Worker (CHW) HIV prevention initiative. The effort expands CHW-led prevention, training, screening, navigation, and culturally aligned outreach prioritizing communities most impacted by HIV.
The grants support integrated screening for HIV, STIs, mental health and substance use, peer navigation, promotores models, pharmacy training, and youth-focused programming to strengthen local prevention networks and reduce stigma.
Gilead (Nasdaq: GILD) reported Phase 3 ARTISTRY-1 and ARTISTRY-2 data showing a once-daily single-tablet investigational regimen bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) maintained virologic suppression through Week 48 in people with HIV who switched from complex regimens or BIKTARVY. No treatment-emergent resistance was observed in ARTISTRY-1; ARTISTRY-2 showed no capsid mutations and limited isolated findings. BIC/LEN was generally well tolerated; lipid and patient-satisfaction improvements were noted versus complex regimens.
Gilead Sciences (Nasdaq: GILD) said its executives will speak at three investor conferences in March 2026: TD Cowen (Mar 3), Leerink Partners (Mar 10) and Barclays (Mar 11).
Live webcasts will be available on the company’s investor site and replays will remain accessible for at least 30 days.
Gilead Sciences (Nasdaq: GILD) agreed to acquire Arcellx (Nasdaq: ACLX) for $115 per share cash plus a $5 CVR, implying an equity value of $7.8 billion. The deal carries a 68% premium to Arcellx’s 30‑day VWAP and is expected to close in Q2 2026, subject to tender and regulatory approvals.
The acquisition gives Gilead full control of anito-cel, whose BLA was accepted by FDA with a PDUFA date of Dec 23, 2026, and is expected to be accretive to EPS in 2028 if approved.
Gilead (Nasdaq: GILD) will present new HIV treatment and prevention data at CROI 2026 (Feb 22–25), including Phase 3 ARTISTRY-1 and ARTISTRY-2 topline results for an investigational single-tablet bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) regimen and PURPOSE program data on twice-yearly lenacapavir for PrEP.
The company will also present data on weekly and twice-yearly treatment strategies, GS-3242 long-acting integrase inhibitor evaluation, and early HIV cure program findings from South Africa.
Gilead Sciences (Nasdaq: GILD) announced a 3.8% increase in its quarterly cash dividend, raising the quarterly dividend to $0.82 per share beginning Q1 2026. The dividend is payable March 30, 2026, to holders of record as of March 13, 2026. Future dividends remain subject to Board approval.
The release also reiterates Gilead's global presence in more than 35 countries and references a planned $32 billion U.S. investment announced in 2025 to support research, jobs and preparedness.
Gilead (Nasdaq: GILD) reported full year 2025 revenue of $29.4 billion and product sales of $28.9 billion. GAAP diluted EPS was $6.78 and non-GAAP diluted EPS was $8.15. Key product moves: Biktarvy sales were $14.3 billion, Descovy $2.8 billion, and Veklury declined to $911 million. The company ended 2025 with $10.6 billion in cash and provided 2026 guidance: product sales $29.6–30.0 billion, GAAP EPS $6.75–7.15, and non-GAAP EPS $8.45–8.85.
Kite, a Gilead company (Nasdaq: GILD) announced FDA approval updating the Yescarta (axicabtagene ciloleucel) label to remove the previous Limitations of Use for patients with relapsed or refractory primary central nervous system lymphoma (R/R PCNSL).
The decision follows a Phase 1 investigator-sponsored safety study that showed a manageable safety profile with no new safety signals, supporting expanded access for this rare, aggressive form of non-Hodgkin lymphoma.
Gilead Sciences (Nasdaq: GILD) will release fourth quarter and full year 2025 financial results and guidance on Tuesday, February 10, 2026 after market close. Management will host a webcast at 4:30 p.m. ET the same day to discuss results and provide a business update.
The live webcast will be available in the Investors section of the company website and will be archived for one year. Corporate headquarters are in Foster City, California.
Gilead (NASDAQ: GILD) announced NEJM publication of positive Phase 3 ASCENT-04/KEYNOTE-D19 results showing Trodelvy plus Keytruda reduced risk of disease progression or death by 35% (HR 0.65; p<0.001) versus Keytruda plus chemotherapy in first-line PD-L1+ (CPS≥10) metastatic TNBC. Median PFS was 11.2 vs 7.8 months (Trodelvy+Keytruda vs Keytruda+chemo; n=221 vs n=222). Fewer discontinuations occurred with the Trodelvy combination (12% vs 31%). No new safety signals were identified; most frequent grade ≥3 events included neutropenia and diarrhea. Gilead has submitted supplemental applications to FDA and EMA.